How much revenue did Antigenics generate this year?
Antigenics has achieved a revenue of 3.22 M USD this year.
Antigenics Revenue 2025
Antigenics Revenue
3.22 M USD
Ticker
ANTI
ISIN
US0370311013
WKN
932075
In 2025, Antigenics's sales reached 3.22 M USD, a -70.87% difference from the 11.05 M USD sales recorded in the previous year.
The Antigenics Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2000 | 3.22 | - |
| 1999 | 11.05 | - |
| 1998 | 6.74 | - |
| 1997 | 0.84 | - |
| 1996 | 2.67 | - |
| 1995 | 1.25 | - |
| 1994 | 0.2 | - |
| 1993 | 0.05 | - |
| 1992 | 0.01 | - |
| 1991 | 0.04 | - |
| 1990 | - | - |
Antigenics Revenue, EBIT, Net Income US0370311013 · 932075
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Antigenics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Antigenics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Antigenics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Antigenics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Antigenics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Antigenics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Antigenics’s growth potential.
Antigenics Revenue, EBIT and net profit per share
| Date | Antigenics Revenue | Antigenics EBIT | Antigenics Net Income |
|---|---|---|---|
| 2000 | 3.22 M undefined | -16.63 M undefined | -17.96 M undefined |
| 1999 | 11.05 M undefined | -15.09 M undefined | -14.09 M undefined |
| 1998 | 6.74 M undefined | -19.41 M undefined | -18.23 M undefined |
| 1997 | 841,000 undefined | -15.79 M undefined | -16.99 M undefined |
| 1996 | 2.67 M undefined | -9.31 M undefined | -8.03 M undefined |
| 1995 | 1.25 M undefined | -9.31 M undefined | -17.43 M undefined |
| 1994 | 200,000 undefined | -9.39 M undefined | -9.05 M undefined |
| 1993 | 50,000 undefined | -6.32 M undefined | -6.23 M undefined |
| 1992 | 10,000 undefined | -4.83 M undefined | -4.71 M undefined |
| 1991 | 40,000 undefined | -2.85 M undefined | -2.91 M undefined |
| 1990 | 0 undefined | -1.98 M undefined | -1.82 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 1990 | 0 USD | -1.98 M USD | -1.82 M USD |
| 1991 | 40,000 USD | -2.85 M USD | -2.91 M USD |
| 1992 | 10,000 USD | -4.83 M USD | -4.71 M USD |
| 1993 | 50,000 USD | -6.32 M USD | -6.23 M USD |
| 1994 | 200,000 USD | -9.39 M USD | -9.05 M USD |
| 1995 | 1.25 M USD | -9.31 M USD | -17.43 M USD |
| 1996 | 2.67 M USD | -9.31 M USD | -8.03 M USD |
| 1997 | 841,000 USD | -15.79 M USD | -16.99 M USD |
| 1998 | 6.74 M USD | -19.41 M USD | -18.23 M USD |
| 1999 | 11.05 M USD | -15.09 M USD | -14.09 M USD |
| 2000 | 3.22 M USD | -16.63 M USD | -17.96 M USD |
Antigenics stock margins US0370311013 · 932075
The Antigenics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Antigenics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Antigenics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Antigenics's sales revenue. A higher gross margin percentage indicates that the Antigenics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Antigenics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Antigenics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Antigenics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Antigenics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Antigenics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Antigenics Margin History
| Antigenics Gross margin | Antigenics Profit margin | Antigenics EBIT margin | Antigenics Profit margin |
|---|---|---|---|
| 2000 | 0 % | -516.71 % | -557.84 % |
| 1999 | 0 % | -136.57 % | -127.52 % |
| 1998 | 0 % | -288.11 % | -270.61 % |
| 1997 | 0 % | -1,877.88 % | -2,020.33 % |
| 1996 | 0 % | -348.58 % | -300.75 % |
| 1995 | 0 % | -746.31 % | -1,396.55 % |
| 1994 | 0 % | -4,695 % | -4,525 % |
| 1993 | 0 % | -12,640 % | -12,460 % |
| 1992 | 0 % | -48,300 % | -47,100 % |
| 1991 | 0 % | -7,125 % | -7,275 % |
| 1990 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 1990 | 0 % | 0 % | 0 % |
| 1991 | 0 % | -7,125 % | -7,275 % |
| 1992 | 0 % | -48,300 % | -47,100 % |
| 1993 | 0 % | -12,640 % | -12,460 % |
| 1994 | 0 % | -4,695 % | -4,525 % |
| 1995 | 0 % | -746.31 % | -1,396.55 % |
| 1996 | 0 % | -348.58 % | -300.75 % |
| 1997 | 0 % | -1,877.88 % | -2,020.33 % |
| 1998 | 0 % | -288.11 % | -270.61 % |
| 1999 | 0 % | -136.57 % | -127.52 % |
| 2000 | 0 % | -516.71 % | -557.84 % |
Antigenics Aktienanalyse
What does Antigenics do?
Antigenics Inc, now Agenus Inc, is a biotechnology company specializing in the research and development of innovative therapies for cancer and infectious diseases. The company is headquartered in Lexington, Massachusetts. The history of Antigenics begins in the late 1980s when the founder, Garo Armen, developed a method for identifying DNA sequences that encode specific proteins. The approach was based on the isolation of lentiviral vectors from human cells, which were then used to transfer the DNA sequences to other cells. This method allowed Antigenics to identify a variety of tumor-specific antigens (TSA) that could serve as potential targets for immunotherapies. In the 1990s, Antigenics focused on developing anti-tumor vaccines based on TSA. The first product was Oncophage, a vaccine made from individual TSA peptides isolated from the patient's tumor cells. Oncophage was tested in Phase II clinical trials in patients with various forms of cancer, including melanoma, renal cell carcinoma, and glioblastoma. Although the vaccine showed significant survival benefits in some studies, it was not approved in the United States. Today, Oncophage is used in Russia and India for the treatment of kidney cancer. In the late 2000s, Antigenics expanded its portfolio to include other immune-oncology approaches such as immune checkpoint protein CTLA-4 modulators, cytotoxic antibodies against cancer cells, and small molecules for immune activation. In 2014, the company was renamed Agenus Inc to reflect its expanded business model. Today, Agenus focuses on the development of immune combination therapies that combine various approaches to activate and modulate the immune system to achieve synergistic effects. The focus is on the use of immune checkpoint inhibitors that relieve T-cell inhibition, as well as the combination of vaccines and cytotoxic antibodies. Agenus' current products include immune checkpoint inhibitor CTLA-4 Ig, which is being tested in Phase III clinical trials for melanoma and lung cancer, and the QS-21 vaccine, which elicits a strong immune response and is used as an adjuvant for other vaccines for the treatment of infectious diseases. Agenus has various divisions, including a division for veterinary immunotherapies, which specializes in the development of vaccines and treatment methods for dogs and horses with cancer. Overall, Agenus has a rich history in the research and development of immunotherapies for the treatment of cancer and infectious diseases. Although the company has experienced setbacks in the past, it remains a key player in the field of immune-oncology and is expected to develop further groundbreaking therapies. Antigenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Antigenics's Sales Figures
The sales figures of Antigenics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Antigenics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Antigenics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Antigenics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Antigenics stock
How much was the turnover of the company Antigenics compared to the previous year?
The revenue of Antigenics has increased by -70.87% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Antigenics?
The revenue of Antigenics is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Antigenics measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Antigenics so important for investors?
The revenue of Antigenics is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Antigenics pay?
Over the past 12 months, Antigenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antigenics is expected to pay a dividend of 0 USD.
What is the dividend yield of Antigenics?
The current dividend yield of Antigenics is .
When does Antigenics pay dividends?
Antigenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Antigenics?
Antigenics paid dividends every year for the past 0 years.
What is the dividend of Antigenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Antigenics located?
Antigenics is assigned to the '-' sector.
Wann musste ich die Aktien von Antigenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Antigenics from 1/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.
When did Antigenics pay the last dividend?
The last dividend was paid out on 1/15/2025.
What was the dividend of Antigenics in the year 2024?
In the year 2024, Antigenics distributed 0 USD as dividends.
In which currency does Antigenics pay out the dividend?
The dividends of Antigenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Antigenics
Our stock analysis for Antigenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antigenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.